Appili Therapeutics Posts C$3.5 Million First-Half Net Loss

Appili Therapeutics Inc. posted a C$3.5 million first-half loss, up C$1.3 million from a year earlier, as the drug developer repositions around dual-use medical technologies.

The net and comprehensive loss covered the six months ended Sept. 30, 2026. Appili recorded a C$2.2 million loss for the six months ended Sept. 30, 2025.

The loss was C$0.03 per share, compared with C$0.02 a year earlier. Government assistance declined by C$500,000, foreign-exchange gains fell by C$400,000, financing costs rose by C$300,000 and administrative expenses increased by C$500,000. A C$400,000 decrease in research and development expenses partly offset those changes.

Cash was C$400,000 on Sept. 30, up from C$40,000 on March 31, 2026. Bloom Burton & Co., a related party, advanced Appili C$1.2 million during the six-month period. The advances were unsecured, carried no interest and had no specific payment terms.

After Sept. 30, Appili’s chief development officer stepped down, and the company laid off three employees. Appili is shifting toward a National Security Healthcare strategy centered on acquiring and advancing medical technologies with dual-use applications.

The company is seeking non-dilutive funding for ATI-1801, a topical paromomycin treatment in development for cutaneous leishmaniasis. Further development depends on securing funding.

“We intend to pursue this strategy with disciplined capital allocation, leveraging partnerships and non-dilutive funding to advance selected programs and create meaningful value for shareholders,” said Dr. Don Cilla, Appili’s president and CEO.